Turn Therapeutics, an innovator in advanced wound and dermatology solutions, is pleased to announce a significant investment commitment from GEM Global Yield LLC SCS ("GEM"), a $3.4 billion private equity and alternative investment group.
"This investment provides both capital flexibility and firepower," said Bradley Burnam, CEO of Turn Therapeutics. "Our IL-31/36 inhibitor for eczema, as well as our onychomycosis program, are top priorities in the near-term. However, discoveries in additional areas, such as thermostable vaccine delivery, have proven highly worthy of additional inquiry. This partnership with GEM ensures that we won't have to pick and choose how we can best serve patients."
The agreement provides Turn Therapeutics with a commitment of up to $75 million for the 36-month period following a public listing of the company's stock. Via a share subscription facility, Turn Therapeutics will be permitted to place stock to GEM at intervals and in amounts determined by Turn's management, with no minimum drawdown obligation.
Turn Therapeutics has secured three FDA medical device clearances, achieved more than 200,000 uses of its technology, and is currently in pursuit of multiple new drug approvals. Turn Therapeutics launched a limited, private financing vehicle on a Regulation Crowdfunding exchange in May 2024 that enables individuals, in addition to institutional and accredited investors, to invest in the company.
GEM has a storied track record of supporting high-growth companies across various sectors, with over 590 completed transactions in 75 countries.
For more information or to set up an interview with Turn Therapeutics CEO, Bradley Burnam, please contact Cooper Rumrill at (202) 980-4968 or cooper@keybridge.biz.
About Turn Therapeutics
Turn Therapeutics is a pharmaceutical and medical device organization specializing in the development of advanced wound and dermatology solutions. Utilizing its proprietary technology and patient-first approach, Turn Therapeutics addresses critical needs in healthcare, aiming to improve access, outcomes, and quality of life. Visit turntherapeutics.com to learn more about the company.
About GEM
GEM Global Yield LLC SCS ("GEM") is a $3.4 billion private equity and alternative investment group with offices in Paris, New York, and Nassau (Bahamas). GEM manages a diverse set of investment vehicles focused on emerging markets and has completed over 590 transactions in 75 countries. Its family of funds and investment vehicles provide GEM and its partners with exposure to: Small-Mid Cap Management Buyouts, Private Investments in Public Equities, and select venture investments.
The statements contained herein may include prospects, statements of future expectations, and other forward-looking statements that are based on management's current views and assumptions and involve known and unknown risks and uncertainties. Actual results, performance, or events may differ materially from those expressed or implied in such forward-looking statements. This transaction will be facilitated exclusively through a registered broker-dealer.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241210259827/en/
Contacts
Cooper Rumrill, (202) 980-4968
cooper@keybridge.biz
